The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling

• Brijal M. Desai ,

  Contributed equally to this work with: Brijal M. Desai, Jessie Villanueva

  Affiliation The Wistar Institute, Philadelphia, Pennsylvania, United States of America

  ⨯
• Jessie Villanueva ,

  Contributed equally to this work with: Brijal M. Desai, Jessie Villanueva

  Affiliation The Wistar Institute, Philadelphia, Pennsylvania, United States of America

  ⨯
• Thierry-Thien K. Nguyen,

  Affiliation The Wistar Institute, Philadelphia, Pennsylvania, United States of America

  ⨯
• Mercedes Lioni,

  Affiliation The Wistar Institute, Philadelphia, Pennsylvania, United States of America

  ⨯
• Min Xiao,

  Affiliation The Wistar Institute, Philadelphia, Pennsylvania, United States of America

  ⨯
• Jun Kong,

  Affiliation The Wistar Institute, Philadelphia, Pennsylvania, United States of America

  ⨯
• Clemens Krepler,

  Affiliation The Wistar Institute, Philadelphia, Pennsylvania, United States of America

  ⨯
• Adina Vultur,

  Affiliation The Wistar Institute, Philadelphia, Pennsylvania, United States of America

  ⨯
• Keith T. Flaherty,

  Affiliation Massachusetts General Hospital, Boston, Massachusetts, United States of America

  ⨯
• Katherine L. Nathanson,

  Affiliation Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America

  ⨯
• Keiran S. M. Smalley,

  Affiliation Department of Molecular Oncology, The Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America

  ⨯
• Meenhard Herlyn

  * E-mail: herlynm@wistar.org

  Affiliation The Wistar Institute, Philadelphia, Pennsylvania, United States of America

  ⨯